Duetact FDA Approval History
FDA Approved: Yes (First approved July 31, 2006)
Brand name: Duetact
Generic name: pioglitazone HCl and glimepiride
Dosage form: Tablets
Company: Takeda Pharmaceuticals North America, Inc.
Treatment for: Diabetes, Type 2
Duetact is a combination of pioglitazone, which directly targets insulin resistance, and glimepiride, a sulfonylurea that acts primarily by increasing the amount of insulin produced by the pancreas. Duetact is indicated for the treatment of type 2 diabetes.
Development timeline for Duetact
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.